Loading...
•
Jun 30, 2023
Lexicon Pharmaceuticals Q2 2023 Earnings Report
Lexicon Pharmaceuticals reported financial results for Q2 2023 and provided a business update.
Key Takeaways
Lexicon Pharmaceuticals reported a net loss of $44.9 million, or $0.22 per share, for the second quarter of 2023. The company received FDA approval for INPEFA and commercially launched it in the U.S. LX9211 is moving into late-stage development for diabetic peripheral neuropathic pain.
INPEFA (sotagliflozin) received FDA approval for the treatment of heart failure.
INPEFA was granted a broad label across the full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes.
LX9211 is moving into late-stage development for the treatment of diabetic peripheral neuropathic pain.
Lexicon commercially launched INPEFA in the U.S. within 30 days of FDA approval.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Revenue by Segment
Revenue by Segment
Net Product Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.com Forward Guidance
This press release contains forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates.
Positive Outlook
- Lexicon's ability to meet its capital requirements.
- Successfully commercialize its approved products.
- Successfully conduct preclinical and clinical development
- Obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines
- Achieve its operational objectives
Challenges Ahead
- Manufacturing risks
- Intellectual property rights risks
- Therapeutic value risks
- Commercial value risks
- Risks relating to strategic alliances
Revenue & Expenses
Visualization of income flow from segment revenue to net income